Transgenic mice can be engineered so that functional endogenous murine antibody gene expression is reduced or eliminated, permitting the preferential expression of introduced transgenes encoding human H2L2 antibodies and human HCAb’s or camelised human HCAb’s.
Harbour Antibodies has developed proprietary transgenic mouse strains capable of efficiently producing human HCAbs, camelised human HCAbs and human H2L2 antibodies following antigen challenge, in the absence of endogenous murine H2L2 antibodies.